Risk of breast and prostate cancer is not associated with increased homozygosity in outbred populations.
Regions of restricted genetic heterogeneity due to identity by descent (autozygosity) are known to confer susceptibility to a number of diseases. Regions of germline homozygosity (ROHs) of 1-2 Mb, the result of autozygosity, are detectable at high frequency in outbred populations. Recent studies have reported that ROHs, possibly through exposing recessive disease-causing alleles or alternative mechanisms, are associated with an increased cancer risk. To examine whether homozygosity is associated with breast or prostate cancer risk, we analysed 500K single-nucleotide polymorphism data from two genome-wide association studies conducted by the Cancer Genetics Markers of Susceptibility initiatives (http://cgems.cancer.gov/). Six common ROHs were associated with breast cancer risk and four with prostate cancer (P<0.01). Intriguingly, one of the breast cancer ROHs maps to 6q22.31-6q22.3, a region that has been previously shown to confer breast cancer risk. Although none of the ROHs remained significantly associated with cancer risk after adjustment for multiple testing, a number of ROHs merit further interrogation. However, our findings provide no strong evidence that levels of measured homozygosity, whatever their aetiology (autozygosity, uniparental isodisomy or hemizygosity), confer an increased risk of developing breast or prostate cancer in predominantly outbred populations.
Enciso-Mora
Victor
V
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
Hosking
Fay J
FJ
Houlston
Richard S
RS
D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D055106:Genome-Wide Association Study; D006720:Homozygote; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics*; D012306:Risk
D005819:Genetic Markers
Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):35-40
19469621
JAMA. 2008 Mar 26;299(12):1437-45
18364486
PLoS Biol. 2006 Mar;4(3):e72
16494531
Nature. 2005 Oct 27;437(7063):1299-320
16255080
PLoS Genet. 2007 Jun;3(6):e90
17542651
Hum Mol Genet. 2008 Oct 15;17(R2):R109-15
18852198
Nat Rev Genet. 2003 Sep;4(9):721-34
12951573
Am J Hum Genet. 1999 Dec;65(6):1493-500
10577902
Hum Mutat. 2006 Nov;27(11):1115-21
16955415
DNA Cell Biol. 2006 Mar;25(3):135-41
16569192
Am J Med Genet. 1989 May;33(1):1-6
2750776
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):135-40
16371466
J Natl Cancer Inst. 1978 Aug;61(2):307-14
277717
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4340-5
18326623
Cancer Res. 2008 Apr 15;68(8):2610-21
18375840
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19942-7
18077426
Lancet. 1991 Oct 12;338(8772):954
1681304
Hum Mol Genet. 2006 Mar 1;15(5):789-95
16436455
Nat Rev Genet. 2009 Sep;10(9):639-50
19687804
Blood. 2007 Apr 15;109(8):3451-61
17170124
Nature. 1991 Jun 20;351(6328):665-7
1675767
Hum Mol Genet. 2007 Jan 1;16(1):1-14
17116639
N Engl J Med. 2000 Jul 13;343(2):78-85
10891514
Nat Genet. 2003 Mar;33 Suppl:238-44
12610533
Nat Genet. 2007 May;39(5):645-9
17401363
Nature. 2007 Jun 28;447(7148):1087-93
17529967
Cancer. 1976 Dec;38(6):2548-50
1069604
Nat Genet. 2007 Jul;39(7):870-4
17529973
Nat Genet. 2008 Mar;40(3):316-21
18264097
Am J Hum Genet. 2007 Sep;81(3):559-75
17701901
Am J Obstet Gynecol. 1981 Nov 15;141(6):629-36
7315892
Genetics. 1989 Nov;123(3):585-95
2513255
Am J Hum Genet. 2006 May;78(5):889-896
16642444
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12216-21
11050243